Wellnara Post-marketing Surveillance in Japan

Written by ClinicalTrials.gov

Category: Bone diseases

Published: 22 July 2011

Condition: Osteoporosis, Postmenopausal
Intervention: Drug: E2/LNG oral (Wellnara, BAY86-5029)
Sponsor: Bayer
Recruiting - verified July 2011

Details: Last Updated: 22 July 2011

Find, Use, Share, Expand Orthopaedic Information

Improving orthopaedic care, education and research using Internet technologies